A liquid biopsy is a blood-based test designed to detect signs of cancer including tumor cell and cancer cell DNA. There are many advantages to a liquid biopsy including being non-invasive, higher availability of samples compared to tissue, suitability for longitudinal monitoring, and better sensitivity.

We offer comprehensive ctDNA screening support for clinical trials, retrospective studies, or method comparisons. Our team of experts can run any kitted solution.

Need a custom panel or solution? We have experience in whole exome sequencing, whole transcriptome sequencing, RNA-Seq, MRD, and bespoke solutions. We also offer bioinformatics and biostatistics support.

 

Panels

  • TSO 500
  • TST 170
  • AVENIO Targeted
  • AVENIO Expanded
  • AVENIO Surveillance
  • AVENIO CGP
  • PGDx Elio

Schedule a consultation with our research team to discuss your specific needs.

About Research Dx
ResearchDx is a full-service diagnostic development organization, providing a ‘start-finish’ partnership for the co-development of companion diagnostics.  At RDx, we design, manage, de-risk and coordinate every aspect of the diagnostics development process, from biomarker discovery, assay design and validation, clinical trial management and logistics, and regulatory submission. As a uniquely technology and platform agnostic solutions provider, we look at all available options to best support your project.
As your single CLIA, CAP and ISO13485 certified partner, we understand the challenges of CDx development and strive to provide a cost effective, de-risked path and clear strategic guidance. RDx provides a flexible process that is agile and adaptable and we dedicate ourselves to the success of our partners.